{"nct_id":"NCT06041802","title":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)","status":"RECRUITING","status_verified_date":"2025-07","start_date":"2023-10-20","start_date_type":"ACTUAL","primary_completion_date":"2028-03-31","primary_completion_date_type":"ESTIMATED","completion_date":"2028-03-31","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["MRK"]}